87 related articles for article (PubMed ID: 16015586)
1. Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer.
Bachmann N; Hoegel J; Haeusler J; Kuefer R; Herkommer K; Paiss T; Vogel W; Maier C
Prostate; 2005 Nov; 65(3):252-9. PubMed ID: 16015586
[TBL] [Abstract][Full Text] [Related]
2. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
3. Association of a CAV-1 haplotype to familial aggressive prostate cancer.
Haeusler J; Hoegel J; Bachmann N; Herkommer K; Paiss T; Vogel W; Maier C
Prostate; 2005 Oct; 65(2):171-7. PubMed ID: 15948133
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
Yoon KA; Gil HJ; Han J; Park J; Lee JS
J Thorac Oncol; 2010 Jan; 5(1):10-6. PubMed ID: 19901851
[TBL] [Abstract][Full Text] [Related]
5. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
6. Association of a TFAM haplotype with aggressive prostate cancer in overweight or obese Mexican Mestizo men.
Granados JB; Méndez JP; Feria-Bernal G; García-García E; Tejeda ME; Rojano-Mejía D; Tapia A; Canto P
Urol Oncol; 2017 Mar; 35(3):111.e9-111.e14. PubMed ID: 27843028
[TBL] [Abstract][Full Text] [Related]
7. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma.
Bachmann N; Haeusler J; Luedeke M; Kuefer R; Perner S; Assum G; Paiss T; Hoegel J; Vogel W; Maier C
Cancer Genet Cytogenet; 2008 Apr; 182(2):103-10. PubMed ID: 18406871
[TBL] [Abstract][Full Text] [Related]
8. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.
Baffoe-Bonnie AB; Smith JR; Stephan DA; Schleutker J; Carpten JD; Kainu T; Gillanders EM; Matikainen M; Teslovich TM; Tammela T; Sood R; Balshem AM; Scarborough SD; Xu J; Isaacs WB; Trent JM; Kallioniemi OP; Bailey-Wilson JE
Hum Genet; 2005 Aug; 117(4):307-16. PubMed ID: 15906096
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
[TBL] [Abstract][Full Text] [Related]
10. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
11. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.
Cramer SD; Chang BL; Rao A; Hawkins GA; Zheng SL; Wade WN; Cooke RT; Thomas LN; Bleecker ER; Catalona WJ; Sterling DA; Meyers DA; Ohar J; Xu J
J Natl Cancer Inst; 2003 Jul; 95(14):1044-53. PubMed ID: 12865450
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J; Lange EM; Isaacs SD; Liu W; Wiley KE; Lange L; Gronberg H; Duggan D; Carpten JD; Walsh PC; Xu J; Chang BL; Isaacs WB; Zheng SL
Prostate; 2008 Apr; 68(5):489-97. PubMed ID: 18213635
[TBL] [Abstract][Full Text] [Related]
13. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.
Chen YC; Giovannucci E; Kraft P; J Hunter D
Carcinogenesis; 2008 May; 29(5):999-1004. PubMed ID: 18375959
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer.
Onen IH; Ekmekci A; Eroglu M; Konac E; Yesil S; Biri H
Exp Biol Med (Maywood); 2008 Dec; 233(12):1608-14. PubMed ID: 18849534
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
16. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
17. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
Ogata R; Matsueda S; Yao A; Noguchi M; Itoh K; Harada M
Prostate; 2004 Sep; 60(4):273-81. PubMed ID: 15264237
[TBL] [Abstract][Full Text] [Related]
18. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness.
Casey G; Neville PJ; Liu X; Plummer SJ; Cicek MS; Krumroy LM; Curran AP; McGreevy MR; Catalona WJ; Klein EA; Witte JS
Hum Mol Genet; 2006 Mar; 15(5):735-41. PubMed ID: 16434482
[TBL] [Abstract][Full Text] [Related]
19. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer.
Camp NJ; Swensen J; Horne BD; Farnham JM; Thomas A; Cannon-Albright LA; Tavtigian SV
Genet Epidemiol; 2005 Apr; 28(3):232-43. PubMed ID: 15593091
[TBL] [Abstract][Full Text] [Related]
20. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk.
Hawkins GA; Cramer SD; Zheng SL; Isaacs SD; Wiley KE; Chang BL; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Prostate; 2002 Nov; 53(3):175-8. PubMed ID: 12386916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
